

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

| | | | | | | | | | | | | |
|--|----------------------------------|------------------|-------|------|-------------------------------|-------------------------|----------------------------------|--------------------|------|----------------|---|-------------|
| 1. PATIENT INITIALS (first, last) PRIVACY | 1a. COUNTRY COSTA RICA | 2. DATE OF BIRTH | | | 2a. AGE 51 Years | 3. SEX Female | 3a. WEIGHT 74.00 kg | 4-6 REACTION ONSET | | | 8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER | |
| | | Day | Month | Year | | | Day | Month | Year | | | |
| | | | | | | | | | | PRIVACY | JUN | 2025 |

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
 gained 6 kg a month ago [Weight increased]
 Symptoms of excessive sleepiness [Hypersomnia]
 high stress [Stress]
 depression [Depression]
 Saxenda has not had an effect [Drug ineffective]

 Case Description: ***This is an auto generated narrative***

 Study ID: 828652-My Healthy Journey

 (Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

| | | |
|--|---|--|
| 14. SUSPECT DRUG(S) (include generic name) #1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL (Continued on Additional Information Page) | | 20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO <input type="checkbox"/> NA |
| 15. DAILY DOSE(S) #1) 1.8 mg, qd | 16. ROUTE(S) OF ADMINISTRATION #1) Subcutaneous | |
| 17. INDICATION(S) FOR USE #1) for weight loss (Weight control) | | 21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA |
| 18. THERAPY DATES(from/to) #1) MAY-2022 / Unknown | 19. THERAPY DURATION #1) Unknown | |

III. CONCOMITANT DRUG(S) AND HISTORY

| | | |
|---|--|--|
| 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) | | |
| 23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Unknown to Ongoing Current Condition Hip deformity (Hip deformity) Unknown to Ongoing Current Condition Hunger (Hunger) | | |

IV. MANUFACTURER INFORMATION

| | | |
|---|---|---|
| 24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 | | 26. REMARKS Medically Confirmed: No |
| | 24b. MFR CONTROL NO. 1472119 | 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD. |
| 24c. DATE RECEIVED BY MANUFACTURER 30-JUN-2025 | 24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER: | |
| DATE OF THIS REPORT 02-SEP-2025 | 25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP: | |

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).

Patient's height: 160 cm.

Patient's weight: 74 kg.

Patient's BMI: 28.906250.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "gained 6 kg a month ago(Weight gain)" beginning on JUN-2025 , "Symptoms of excessive sleepiness(Sleep excessive)" with an unspecified onset date , "high stress(Stress)" with an unspecified onset date , "depression(Depression)" with an unspecified onset date , "Saxenda has not had an effect(Lack of drug effect)" beginning on JUN-2025 and concerned a 51 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from MAY-2022 to JUN-2025 for "for weight loss",

Dosage Regimens:

Saxenda: ??-MAY-2022 to Not Reported, Not Reported to ??-JUN-2025;

Current Condition: Problem in the hip, hunger, anxiety.

Lab Data included:

Test Date: 2023

Lab Data Test as Reported: weight

Test Name: Weight

Comments: On an unspecified date in 2023 patient reported to have lost approximately 15kg with saxenda.

Test Date: OCT-2024

Lab Data Test as Reported: weight

Test Name: Weight

Comments: On an unknown date in Oct-2024, the patient gained weight

Test Date: 2025

Lab Data Test as Reported: weight

Test Name: Weight

Comments: On an unspecified date in 2025 patient reported to have gained 6kg weight.

Batch Numbers:

Saxenda: ASKU, ASKU;

Action taken to Saxenda was reported as Product discontinued.

The outcome for the event "gained 6 kg a month ago(Weight gain)" was Not recovered.

The outcome for the event "Symptoms of excessive sleepiness(Sleep excessive)" was Not Reported.

The outcome for the event "high stress(Stress)" was Not Reported.

The outcome for the event "depression(Depression)" was Not Reported.

The outcome for the event "Saxenda has not had an effect(Lack of drug effect)" was Not recovered.

Reporter's causality (Saxenda) -

gained 6 kg a month ago(Weight gain) : Possible

Symptoms of excessive sleepiness(Sleep excessive) : Unknown

high stress(Stress) : Unlikely

depression(Depression) : Unlikely

Saxenda has not had an effect(Lack of drug effect) : Possible

Company's causality (Saxenda) -

gained 6 kg a month ago(Weight gain) : Possible

Symptoms of excessive sleepiness(Sleep excessive) : Unlikely

high stress(Stress) : Unlikely

depression(Depression) : Unlikely

Saxenda has not had an effect(Lack of drug effect) : Possible

Reporter Comment: The patient started using Saxenda in 2022, and in 2023, mentions that the experience was "super good" as approximately 15 kg were lost.

ADDITIONAL INFORMATION

13. Lab Data

| # | Date | Test / Assessment / Notes | Results | Normal High / Low |
|---|----------|---|---------|-------------------|
| 1 | 2023 | Weight | | |
| | | On an unspecified date in 2023 patient reported to have lost approximately 15kg with saxenda. | | |
| 2 | OCT-2024 | Weight | | |
| | | On an unknown date in Oct-2024, the patient gained weight | | |
| 3 | 2025 | Weight | | |
| | | On an unspecified date in 2025 patient reported to have gained 6kg weight. | | |

13. Relevant Tests

On an unspecified date in 2023 patient reported to have lost approximately 15kg weight with saxenda.
On an unspecified date in 2025 patient reported to have gained 6kg weight.
On an unknown date in Oct-2024, the patient gained weight

14-19. SUSPECT DRUG(S) continued

| 14. SUSPECT DRUG(S) (include generic name) | 15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN | 17. INDICATION(S) FOR USE | 18. THERAPY DATES (from/to); 19. THERAPY DURATION |
|--|---|----------------------------------|--|
| #1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL; Regimen #2 | UNK(resumed in March or April 2025); Subcutaneous | for weight loss (Weight control) | Unknown / JUN-2025; Unknown |

23. OTHER RELEVANT HISTORY continued

| From/To Dates | Type of History / Notes | Description |
|--------------------|-------------------------|--------------------|
| Unknown to Ongoing | Current Condition | Anxiety (Anxiety); |